Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children.

Abstract

We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.

• Authors: Ruth A Karron, Jocelyn San Mateo, Bhagvanji Thumar, Anne Schaap-Nutt, Ursula J Buchholz, Alexander C Schmidt, Emmalene J Bartlett, Brian R Murphy, Peter L Collins
• Journal: Journal of the Pediatric Infectious Diseases Society (J Pediatric Infect Dis Soc) Vol. 4 Issue 4 Pg. e143-6 (Dec 2015) ISSN: 2048-7207 [Electronic] England
• PMID: 26582883 (Publication Type: Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)
• Copyright: © The Author 2014. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: [email protected].

Chemical References

• Antibodies, Viral
• Parainfluenza Vaccines
• Vaccines, Attenuated

Topics

• Adult
• Antibodies, Viral (blood)
• Child, Preschool
• Double-Blind Method
• Humans
• Infant
• Parainfluenza Vaccines (therapeutic use)
• Parainfluenza Virus 1, Human
• Paramyxoviridae Infections (epidemiology, prevention & control)
• Vaccines, Attenuated (therapeutic use)